Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 17/20 | 0.49 |
| ▸ | JAK1 | P23458 | 13/20 | 0.49 |
| ▸ | TYK2 | P29597 | 3/20 | 0.49 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL99837 | 0.91 | JAK2 (0.48) | JAK2JAK1TYK2TYRO3HDAC6 | |
| Trifluoroacetic Acid SCHEMBL103185 | 0.90 | JAK2 (0.48) | JAK2JAK1TYK2TYRO3HDAC6 | |
| Trifluoroacetic Acid SCHEMBL4088137 | 0.86 | GRM4 (0.49) | JAK2JAK1TYK2 | |
| SCHEMBL101518 | 0.80 | JAK2 (0.55) | JAK2JAK1TYK2TYRO3HDAC6 | |
| Trifluoroacetic Acid SCHEMBL4086281 | 0.80 | JAK2 (0.49) | JAK2JAK1TYK2 | |
| Trifluoroacetic Acid SCHEMBL102460 | 0.78 | JAK2 (0.47) | JAK2JAK1TYK2HDAC6 | |
| Trifluoroacetic Acid SCHEMBL4093301 | 0.76 | GRM4 (0.49) | JAK2JAK1TYK2 | |
| Trifluoroacetic Acid SCHEMBL4086078 | 0.76 | JAK1 (0.49) | JAK2JAK1TYK2 | |
| SCHEMBL29540396 | 0.76 | GRM4 (0.55) | JAK2JAK1TYK2TYRO3 | |
| SCHEMBL100017 | 0.76 | GRM4 (0.55) | JAK2JAK1TYK2TYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137681-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2013-05-30 | — | — | US | disclosed |
| US-8415362-B2 | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2013-04-09 | — | — | US | disclosed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137681-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | JAK2 3/4885JAK1 2/4885TYK2 4/4885 |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | JAK2 3/4885JAK1 2/4885TYK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.